Asst. Prof. Dr. Wang Yi is a co-founder of Medical Innovation Development and Assessment Support (MIDAS). His research areas include early health technology assessment, traditional health technology assessment, population’s preference for health and healthcare, and economic evaluation/analysis using real-world data and observational data. He is als

Thanchanit Thaipitakwong is currently a Senior Content Creator at HITAP, responsible for planning and delivering research communication to the public and developing content in various formats tailored to different audiences and platforms. With a background in pharmacy and experience in medical communication, she focuses on making complex academic c

Benjarin Santatiwongchai is Head of Communication for HITAP. Having studied BSc in Pharmacy from Mahidol University, her knowledge in current and emerging medical technologies and interventions has led her to become involved with Health Technology Assessment. In 2012, she completed her MSc in Health Economics at the University of York. She is now a

Katika Akksilp MD PhD is a researcher at the Institute of Medical Research and Technology Assessment and currently serves as Head of the Precise Interventions (PI) unit at Health Intervention and Technology Assessment Program (HITAP) Foundation. He earned his doctorate in Public Health Research from Saw Swee Hock School of Public Health, National U

Shiela is an Associate at the HITAP International Unit. She holds a doctoral degree in Microbiology and currently leads antimicrobial resistance (AMR)-related projects at HITAP, in collaboration with international partners such as the University of Oxford, City St George’s University of London, and global organizations including the World Health Or

Jarawee Sukmanee is a researcher at the Health Intervention and Technology Assessment Program Foundation (HITAP). With a background as a medical doctor and epidemiologist, she applies advanced analytical techniques to evaluate the cost-effectiveness of health interventions. She plays a key role in generating evidence to support national policy deci

Pritaporn Kingkaew has been a researcher at HITAP since 2007. She graduated from a joint programme between Srinakharinwirot University, Thailand and the University of Nottingham, UK in 2007 with a Bachelor’s degree in Pharmacy. In 2009, she was awarded the HITAP scholarship to pursue a Master’s degree in Health Economics from the University of York

Yot Teerawattananon is a Assistant Secretary General of the Foundation & Senior Researcher of the Health Intervention and Technology Assessment Program (HITAP), which is a semi-autonomous research institute of Thailand’s Ministry of Public Health. The works of HITAP have been used to inform policy decisions regarding the adoption of medicines,

In Thailand, the prevalence of chronic kidney disease (CKD) is 17.5% of the population (Ingsathit et al., 2010). According to Thailand’s National Health Security Office (2021), in each year, this public health agency spends approximately 10,000 million Baht in renal dialysis and 1,000 million Baht for the CKD treatment and other related expenses.

Kidney failure (KF)[1] is a life-threatening disease that requires either kidney transplantation or dialysis for survival (1, 2). As of 2019, it was estimated that globally, 1.4 million deaths occurred on account of chronic kidney disease (CKD) (3). The cost of treatment for KF is also high, leading to catastrophic household expenditure to househo